Abstract
The purposes of this study were to determine the expression profiles of microRNA-34a (miR-34a) in human gastric cancer cell line (SGC-7901) and cisplatin-resistant cell lines (SGC-7901/DDP), and to establish the correlation between miR-34a expression profile and the sensitivity of human gastric cancer cell to cisplatin-based pattern, thereby providing new methods and strategies for treating gastric cancer. Gastric cancer cell line (SGC-7901) and cisplatin-resistant cell line (SGC-7901/DDP) were cultivated in vitro, respectively. Quantitative real-time PCR (qRT-PCR) and Western blot were utilized to determine the expression profiles of miR-34a and survivin in both gastric cancer cell lines. With miR-34a mimic and miR-34a inhibitor transfected into SGC-7901 and SGC-7901/DDP for 48 h, post-transfection changes of miR-34a expression was determined; the effects of miR-34a ectopic expression on the viability of cisplatin-induce gastric cancer cell were assayed by the MTT method. The effects of miR-34a ectopic expression on apoptosis of cisplatin-induce gastric cancer cell were determined by Annexin V/propidium iodide (PI) double staining method and flow cytometry. The effects of miR-34a ectopic expression on the AKT and p-AKT expression of cisplatin-induce gastric cancer cells were determined by Western blot and flow cytometry with the PI3K pathway inhibitor Wortmannin. As shown by qRT-PCR and Western blot analyses, the expression of miR-34a in cisplatin-resistant cell lines decreased significantly in comparison to that of SGC-7901 cell line (p < 0.05), while significant up-regulation of survivin expression was also observed (p < 0.05). Compared with the control group, the expression of miR-34a increased significantly in SGC-7901 cells transfected with miR-34a mimic for 48 h (p < 0.01). After miR-34a inhibitor transfection, the expression of miR-34a decreased significantly (p < 0.05). The viability of cisplatin-induce gastric cancer cells increased significantly (p < 0.05) with significant decrease of apoptosis after miR-34a expression inhibition, as demonstrated by MTT and flow cytometry with miR-34a over-expression, the viability of cisplatin-induce gastric cancer cells decreased significantly (p < 0.05), with significant apoptosis increase (p < 0.05). As shown by Western blot and flow cytometry, in comparison to the control group, Wortmannin could inhibit miR-34a inhibitor and DDP induced up-regulation of p-AKT significantly (p < 0.05) and stimulated apoptosis. In conclusion, miR-34a expression was down-regulated in cisplatin-resistant cell lines. miR-34a over-expression could improve the sensitivity of gastric cancer cells against cisplatin-based chemotherapies, with PI3K/AKT/survivin signaling pathway possibly involved in the mechanism.
Similar content being viewed by others
References
Li XJ, Xie HL, Lei SJ, et al. Reduction of CAII expression in gastric cancer: correlation with invasion and metastasis. Chin J Cancer Res. 2012;24:196–200.
Shan F, Ji J. Updating advances and controversies on the multidisciplinary therapy of gastric cancer. Transl Gastrointest Cancer. 2012;1:151–60.
Hu B, El Hajj N, Sittler S, et al. Gastric cancer: classification, histology and application of molecular pathology. J Gastrointest Oncol. 2012;3:251–61.
Wu A, Ji J. The 7th National Gastric Cancer Academic Conference: focus on translational research in gastric cancer. Transl Gastrointest Cancer. 2012;1:277–83.
Leja M, Wex T, Malfertheiner P. Markers for gastric cancer premalignant lesions: where do we go? Dig Dis. 2012;30:268–76.
Sun Y, Tian MM, Zhou LX, et al. Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population. Chin J Cancer Res. 2012;24:18–22.
Zhang CD, Zeng YJ, Li HW, et al. Neoadjuvant chemotherapy for nonmetastatic esophago-gastric adenocarcinomas: a systematic review and meta-analysis. Cancer Invest. 2013.
Correa P. Gastric cancer: overview. Gastroenterol Clin North Am. 2013;42(2):211–7.
Zhao X, Li X, Yuan H. microRNAs in gastric cancer invasion and metastasis. Front Biosci. 2013;18:803–10.
Sanford M. S-1 (teysuno((R))): a review of its use in advanced gastric cancer in non-Asian populations. Drugs. 2013;73(8):845–55.
Ema A, Yamashita K, Sakuramoto S, et al. Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer. 2013.
Chen XL, Chen XZ, Yang C, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One. 2013;8(4):e60320.
Taketa T, Sudo K, Wadhawa R, et al. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15(2):146–51.
Shi WT, Wei L, Xiang J, et al. Chinese patients with gastric cancer need targeted adjuvant chemotherapy schemes. Asian Pac J Cancer Prev. 2012;13(10):5263–72.
Huang JY, Xu YY, Sun Z, et al. Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4379–85.
Kong YW, Ferland-McCollough D, Jackson TJ, et al. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–258.
Wiwanitkit S, Wiwanitkit V. MicroRNA from tuberculosis RNA: a bioinformatics study. J Thorac Dis. 2012;4(3):296–7.
Lee CH, Chiu YC, Wang LB, Kuo YL, Chuang EY, Lai LC, et al. Common applications of next-generation sequencing technologies in genomic research. Transl Cancer Res. 2013;2(1):33–45.
Zhou X, Yuan P, He Y. Role of microRNAs in peripheral artery disease (review). Mol Med Report. 2012;6(4):695–700.
McDaniel K, Correa R, Zhou T, et al. Functional role of microvesicles in gastrointestinal malignancies. Ann Transl Med. 2013;1:4.
Ui-Tei K, Nishi K, Takahashi T, et al. Thermodynamic control of small RNA-mediated gene silencing. Front Genet. 2012;3:101.
Yang JS, Maurin T, Lai EC. Functional parameters of Dicer-independent microRNA biogenesis. RNA. 2012;18(5):945–57.
Weiland M, Gao XH, Zhou L, et al. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850–9.
Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012;12(9):1221–39.
Yamamoto H, Adachi Y, Taniguchi H, et al. Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer. World J Gastroenterol. 2012;18(22):2745–55.
Wong MY, Yu Y, Walsh WR, et al. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol. 2011;38(5):1189–95.
O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201.
Cha YH, Kim NH, Park C, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11(7):1273–81.
Balca-Silva J, Neves SS, Goncalves AC, et al. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res. 2012;32(5):1603–9.
Cao W, Fan R, Wang L, et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol. 2013;34(2):963–71.
Franchina T, Amodeo V, Bronte G, et al. Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. J Cell Physiol. 2013.
Li XJ, Ji MH, Zhong SL, et al. MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res. 2012;43(7):514–21.
Yao Y, Suo AL, Li ZF, et al. MicroRNA profiling of human gastric cancer. Mol Med Report. 2009;2(6):963–70.
Wong KY, Yu L, Chim CS. DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics. 2011;3(1):83–92.
Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLoS One. 2012;7(5):e37601.
Shen Z, Zhan G, Ye D, et al. MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. Med Oncol. 2012;29(4):2473–80.
Jagadeesh D, Smith MR. Novel targeted therapies in peripheral T cell lymphoma. Discov Med. 2013;15(85):367–78.
Morotti M, Becker C, Menada MV, et al. Targeting tyrosine-kinase in ovarian cancer. Expert Opin Investig Drugs. 2013.
Lubin J, Markowska A, Knapp P. Factors affecting response of chemotherapy in women with ovarian cancer. Eur J Gynaecol Oncol. 2012;33(6):644–7.
Breier A, Gibalova L, Seres M, et al. New insight into P-glycoprotein as a drug target. Anticancer Agents Med Chem. 2013;13(1):159–70.
De Luca A, Maiello MR, D'Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 2012;16 Suppl 2:S17–27.
Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012;40(1):139–46.
Du F, Wu X, Liu Y, et al. Acquisition of paclitaxel resistance via PI3K-dependent epithelial–mesenchymal transition in A2780 human ovarian cancer cells. Oncol Rep. 2013.
Conflicts of interest
The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
W. Cao and W. Yang contributed equally to this study.
Rights and permissions
About this article
Cite this article
Cao, W., Yang, W., Fan, R. et al. miR-34a regulates cisplatin-induce gastric cancer cell death by modulating PI3K/AKT/survivin pathway. Tumor Biol. 35, 1287–1295 (2014). https://doi.org/10.1007/s13277-013-1171-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-013-1171-7